Computerized transrectal ultrasound of the prostate in a multicenter setup (C-TRUS-MS): detection of cancer after multiple negative systematic random and in primary biopsies
Abstract:The results indicate that C-TRUS-MS "online" achieves similar results as the stand-alone system, independent of the user even with little experience in the method. Furthermore, C-TRUS-MS for the first time is able to detect carcinomas in patients without prior biopsies in a high number by taking only six targeted biopsies.
“…Furthermore, PCa detection rates with 39-139 systematic cores have been reported at 45%, which is a lower detection rate than our results using a median of 5 E-TRUS targeted cores [14]. Recently, Grabski et al [15] reported in a prospective multicenter study PCa detection rates even in patients without prior biopsies, up to 41% by taking only six targeted cores when using a computerbased analysis of the TRUS signal. Furthermore, even we know that our technique needs expensive equipment, saturation biopsy has significantly higher costs of at least 5,000 USD compared with standard systematic biopsy.…”
“…Furthermore, PCa detection rates with 39-139 systematic cores have been reported at 45%, which is a lower detection rate than our results using a median of 5 E-TRUS targeted cores [14]. Recently, Grabski et al [15] reported in a prospective multicenter study PCa detection rates even in patients without prior biopsies, up to 41% by taking only six targeted cores when using a computerbased analysis of the TRUS signal. Furthermore, even we know that our technique needs expensive equipment, saturation biopsy has significantly higher costs of at least 5,000 USD compared with standard systematic biopsy.…”
“…Our detection rate (20%) is lower than the rates reported in the literature [23] [24] [25] [26]. This difference is explained by our "blind" method which limits the detection of small non-palpable fireplaces DRE.…”
Background: Diagnosis of prostate cancer is certified by histology true prostate biopsies. The aim of our study was to evaluate our prostate biopsy method. Material and Methods: It was a prospective study including patients underwent prostate biopsy. Inclusion criteria were prostate specific antigen (PSA) level up to 4ng/ml and/or abnormal prostate at digital rectal examination. Patients who had risk factors of bleeding have been excluded of the study. The preparation before biopsy included antibioprophylaxy (Ciprofloxacine-Tinidazole) and rectal hypertonic cleaning (Normacol*). Twelve cores have been taken in each prostate by transrectal digital-guided way, using Biopty Gun 18 Gauge. Local anesthesia has been done previously by intrarectal application of 20 ml of gel of Lidocaïne. Two other cores were taken into each abnormal area at rectal examination. The follow-up have been done during twelve weeks. Results: Eighty patients of 65 years of age were included. Nine patients had familial history of prostate cancer. PSA levels ranged from 5 to 6400 ng/ml with a median of 26.77 ng/ml ± 11.2. Complications occurred in 11.25% of patients, principally infectious complications which caused death of one patient by septicemia. The rate of cancer detection was 20%. Prostate abnormality at digital rectal examination and the presence of familial history of prostate cancer were not predictive factors of the presence of cancer on cores. Conclusion: Our prostate biopsy method is limited by the lack of ultrasonographic guidance and is at important risk of infectious complications.
“…There are only a few studies regarding the ANNA/C-TRUS technology. To date, it was able to be shown that prostate cancer was able to be detected in 31 of 75 patients (41 %) via targeted 6-core biopsy of areas suspicious on ANNA-C-TRUS [19]. These results were able to be confirmed in another study with 20 patients.…”
The detection, staging, and active monitoring of prostate cancer are common clinical questions. The best method for answering these questions is multiparametric MRI. Ultrasound elastography also seems to be suitable for the detection of significant prostate cancer. The new PI-RADS Version 2 claims to eliminate the limitations of PI-RADS Version 1 and to allow globally recognized standardized diagnostic reporting.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.